A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Key claim: A Phase 3 trial is evaluating whether pelabresib (a BET bromodomain inhibitor) combined with ruxolitinib improves clinical outcomes compared to ruxolitinib alone in JAK-inhibitor-naive patients with PMF, PPV-MF, or PET-MF.
Abstract
The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.
Why this matters
Pelabresib’s Phase 3 evaluation in combination with ruxolitinib marks the most advanced clinical test of BET bromodomain inhibition in myelofibrosis, directly relevant to PMF and post-PV/post-ET MF natural history where ruxolitinib monotherapy yields incomplete spleen and symptom responses. As a JAK-inhibitor-naive frontline combination strategy, it could reshape first-line treatment expectations for PMF and parallels other late-stage ruxolitinib-combination trials (e.g., SENTRY/selinexor) competing to redefine upfront MF care.